AYTUNasdaqPharmaceutical PreparationsFiscal year ends June 30
AYTU BIOPHARMA, INC
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 22, 2026
$1.96−0.08 (-3.92%)
Close on Oct 19, 2026
- Market cap
- $37.82M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.33 (−14.41%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
AYTU BIOPHARMA, INC saw revenue fall 13.3% to $57.57M over the twelve months to Jun 30, 2026. Free cash flow was $3.25M.
Revenue
$57.57M
-13.3% vs. a year earlier
Operating income
-$8.32M
TTM Q4 2026
Free cash flow
$3.25M
TTM Q4 2026
EPS, diluted
-$1.66
TTM Q4 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $37.82M
- P/E ratio
- –
- Price to sales
- 0.66
- Price to book
- 1.07
- Dividend yield
- –
- Free cash flow yield
- 8.60%
Fundamentals
- Revenue
- $57.57M
- Net income
- -$14.25M
- EPS, diluted
- -$1.66
- Free cash flow
- $3.25M
- Book value per share
- $1.83
- Diluted shares
- 19M
Fifteen years at a glance
Fiscal years 2011 to 2026, USD
Revenue
$57.57M-13.3% YoY
Gross profit
$36.82M-19.7% YoY
Operating income
-$8.32M
Net income
-$14.25M
EPS, diluted
–
Free cash flow
$3.25M
Reported period